Adamas Pharmaceuticals
Supernus Pharmaceuticals is an award-winning biopharmaceutical company with over 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases. The company's mission is to improve the lives of patients suffering from CNS diseases through innovative research, development, and strategic collaborations. Supernus focuses on developing novel treatments in neurology and psychiatry, with a diverse portfolio of products including Qelbree, Trokendi XR, Oxtellar XR, and others. The company values integrity, commitment, innovation, and caring, and emphasizes a culture of ethical conduct, employee growth, and patient-centricity.
Industries
Nr. of Employees
medium (51-250)
Adamas Pharmaceuticals
9715 Key West Avenue, Rockville, MD 20850
Patents
Products
Commercial CNS pharmaceutical portfolio
A marketed portfolio of pharmaceutical products indicated for central nervous system disorders, including therapeutic areas such as ADHD, epilepsy, migraine and Parkinson’s disease.
Clinical-stage product candidates for CNS disorders
Internal product candidates in development for CNS conditions, with multiple programs in clinical phases aimed at indications such as treatment-resistant depression and severe epilepsy.
Commercial CNS pharmaceutical portfolio
A marketed portfolio of pharmaceutical products indicated for central nervous system disorders, including therapeutic areas such as ADHD, epilepsy, migraine and Parkinson’s disease.
Clinical-stage product candidates for CNS disorders
Internal product candidates in development for CNS conditions, with multiple programs in clinical phases aimed at indications such as treatment-resistant depression and severe epilepsy.
Services
End-to-end clinical development support including study design, execution, data management and trial disclosure.
Regulatory strategy, submission preparation, compliance program implementation and transparency reporting.
Quality systems, GMP operations and supply chain management, including coordination of outsourced manufacturing.
U.S. commercial launches and ongoing specialty sales, marketing, and access support for CNS medicines.
Centralized patient support services for access, insurance and product inquiries and a medical information request service for HCPs.
Administration of grants to medical, educational and other organizations and financial support for independent medical education.
End-to-end clinical development support including study design, execution, data management and trial disclosure.
Regulatory strategy, submission preparation, compliance program implementation and transparency reporting.
Quality systems, GMP operations and supply chain management, including coordination of outsourced manufacturing.
U.S. commercial launches and ongoing specialty sales, marketing, and access support for CNS medicines.
Centralized patient support services for access, insurance and product inquiries and a medical information request service for HCPs.
Administration of grants to medical, educational and other organizations and financial support for independent medical education.
Expertise Areas
- Clinical trial management
- Regulatory compliance and submissions
- GMP manufacturing and quality systems
- Supply chain and outsourced manufacturing operations
Key Technologies
- Drug delivery platform technologies
- Clinical trial platforms and electronic data capture (EDC) systems
- Biostatistics and biometrics
- Pharmacovigilance and safety reporting systems
News & Updates
Supernus announced the approval of Qelbree, a new medication for ADHD, with prescribing information and boxed warning.
2021 Forbes America's Best Small Companies
Recognition for Supernus as one of America's best small companies in 2021.
2020 Best of Rockville Awards - Pharmaceutical Company
Supernus received the 2020 Best of Rockville Award for pharmaceutical companies.
Financial Times The Americas’ Fastest Growing Companies 2020
Supernus was recognized as one of the fastest growing companies in the Americas in 2020.
Washington Business Journal Largest Public Companies 2019
Supernus was listed among the largest public companies by Washington Business Journal in 2019.
Fortune 100 Fastest Growing Companies
Supernus was included in Fortune's list of 100 fastest growing companies.
Supernus announced the approval of Qelbree, a new medication for ADHD, with prescribing information and boxed warning.
2021 Forbes America's Best Small Companies
Recognition for Supernus as one of America's best small companies in 2021.
2020 Best of Rockville Awards - Pharmaceutical Company
Supernus received the 2020 Best of Rockville Award for pharmaceutical companies.
Financial Times The Americas’ Fastest Growing Companies 2020
Supernus was recognized as one of the fastest growing companies in the Americas in 2020.
Washington Business Journal Largest Public Companies 2019
Supernus was listed among the largest public companies by Washington Business Journal in 2019.
Fortune 100 Fastest Growing Companies
Supernus was included in Fortune's list of 100 fastest growing companies.